Citius Pharmaceuticals, Inc.-Tampa Dinner

2223 North Westshore Boulevard,Tampa FL 33607

07 July, 2021

Description

Come learn more about Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) and their management team *Due to limited seating, please make sure each individual registers accordingly. You will not be permitted to attend the event without proper registration. Citius Pharmaceuticals, Inc.  (NASDAQ:  CTXR)Wednesday, July 7, 2021The Capital Grille2223 North Westshore BlvdTampa, FL 33607Promptly at 5:30 PMJoin Citius Pharmaceuticals, Inc. Chairman Leonard Mazur for this exclusive corporate presentation, followed by a Q & A session moderated by Bear Creek Capital, featuring questions taken from the audience. We hope you can join our presentation About Citius Phamaceuticals, Inc.Citius Pharmaceuticals (NASDAQ: CTXR) is a specialty pharmaceutical company dedicated to the development and commercialization of important new drug products for growing markets. Citius is currently advancing three proprietary product candidates: Mino-Lok®, CITI-002 (halobetasol-lidocaine formulation) and CITI-101 (Mino-Wrap). Citius believes the markets for its products are large and underserved by the current standard of care. Company HighlightsCitius is committed to developing therapies for unmet medical needs with cost-effective products in high growth categories with low developmental risk. Mino-Lok product has advanced to Phase 3 clinical studies. CITI-101 (Mino-Wrap) is a bio-absorbable film impregnated with minocycline and rifampin for reducing acute inflammation and microbial colonization of breast tissue expanders used in breast reconstruction surgeries following mastectomies. More information on this product will be coming soon. CITI-002 is being developed for symptomatic relief of hemorrhoids. CITI-002 combines the high-potency steroid, halobetasol, with lidocaine. Citius has an experienced management team with demonstrated success in developing and commercializing novel pharmaceutical products. In the NewsCitius Pharmaceuticals Expands Scientific Advisory Board with Addition of Dr. John Laffey, Expert in Stem Cell and Gene Therapies for ARDS Citius Pharmaceuticals Achieves Next Interim Analysis Milestone in its Mino-Lok® Phase 3 Trial Citius Pharmaceuticals to be Added to Russell 2000® Index Citius Pharmaceuticals to Feature Updated Positive Interim Results of i-MSC Study During Poster Presentation at International Society for Cell and Gene Therapy Citius Pharmaceuticals, Inc. Announces Appointment of Ilanit Allen as Vice President, Corporate Communications and Investor Relations Citius Pharmaceuticals, Inc. Reports Second Fiscal Quarter 2021 Financial Results and Provides General Business Update Citius Pharmaceuticals Reports Strong Clinical Community Engagement During Mino-Lok® Phase 3 Trial-Related Webinar Citius Pharmaceuticals CEO Myron Holubiak Featured in Benzinga Interview Citius Pharmaceuticals Announces Closing of $76.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules Citius Pharmaceuticals Issues Shareholder Letter with Corporate Update on Recent Achievements and Anticipated Milestones for 2021 Presentation Format:  5:30 p.m. to 7:00 p.m. – Check In & Networking 6:00 p.m. -7:00 p.m. - Presentation and Dinner Contact: Raymond Oliver CEO, Bear Creek Capital 321-439-2120 [email protected]